hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06299072, orgStudyIdInfo id: PEP-2303, briefTitle: A Cross-sectional Online Survey Among Saudi Arabian Population in the Age Group 18-40 Years to Assess Whole Grain (WG) Awareness, Consumption Levels, and Dietary Habits Around Breakfast, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-09-05, primaryCompletionDateStruct date: 2023-09-19, completionDateStruct date: 2023-09-19, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: PepsiCo Global R&D, class: INDUSTRY, descriptionModule briefSummary: In this online survey conducted suing the YouGov consumer insights panel, the primary aims of this study are to provide for the first time an estimate of consumer awareness regarding wholegrains; their definitions and knowledge of potential benefits in the Saudi Arabia adult population and the he estimated consumption amongst Saudi consumers.Secondary Objectives are to assess the breakfast habit, oat consumption \& health concerns amongst Saudi consumers; identify socio-demographic and consumer characteristics associated with breakfast consumption, the types of foods consumed at breakfast, and fill gaps in knowledge regarding breakfast eating habits, commonly consumed breakfast foods., conditionsModule conditions: Diet, Healthy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 814, type: ACTUAL, armsInterventionsModule interventions name: Survey, outcomesModule primaryOutcomes measure: Consumer awareness regarding wholegrains, primaryOutcomes measure: Consumer definitions of wholegrains, primaryOutcomes measure: Consumer knowledge of potential benefits of wholegrains, primaryOutcomes measure: Wholegrain consumption, secondaryOutcomes measure: Breakfast habits, secondaryOutcomes measure: Oat consumption, secondaryOutcomes measure: Health concerns, secondaryOutcomes measure: Socio-demographics associated with breakfast consumption, secondaryOutcomes measure: Consumer characteristics associated with breakfast consumption, secondaryOutcomes measure: Types of foods consumed at breakfast, secondaryOutcomes measure: Fill gaps in knowledge regarding breakfast eating habits, secondaryOutcomes measure: Commonly consumed breakfast foods, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule locations facility: Remote, no facility visits, city: Riyadh, country: Saudi Arabia, geoPoint lat: 24.68773, lon: 46.72185, hasResults: False
protocolSection identificationModule nctId: NCT06299059, orgStudyIdInfo id: Compliance, briefTitle: Intermittent Oro-esophageal Tube on Rehabilitation Therapy Compliance in Stroke Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-07, completionDateStruct date: 2024-07, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Zeng Changhao, class: OTHER, descriptionModule briefSummary: The aim of this clinical trial is to compare Rehabilitation Therapy Compliance of ischemic stroke patients who receive enteral nutrition support through either Intermittent Oro-esophageal Tube or Nasogastric Tube. Patients will be randomly assigned to either an observation group or a control group, with both groups receiving routine rehabilitation treatment. The observation group will receive enteral nutrition support through Intermittent Oro-esophageal Tube, while the control group will receive it through Nasogastric Tube. Researchers will then compare Rehabilitation Therapy Compliance of the two groups., conditionsModule conditions: Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Intermittent Oro-esophageal Tube Feeding, interventions name: Nasogastric Tube Feeding, outcomesModule primaryOutcomes measure: Rehabilitation Treatment Compliance Questionnaire, secondaryOutcomes measure: Patient Health Questionnaire-9, secondaryOutcomes measure: Swallowing Quality of Life questionnaire, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06299033, orgStudyIdInfo id: HPS-NP1-101, briefTitle: A Safety and Tolerability Study of Human Forebrain Neural Progenitor Cells Injection (hNPC01) in Subjects With Chronic Ischemic Stroke, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-09, primaryCompletionDateStruct date: 2024-08-30, completionDateStruct date: 2025-12-30, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Hopstem Biotechnology Inc., class: INDUSTRY, descriptionModule briefSummary: The principal aims of the clinical investigation involve assessing the safety profile and MTD of human forebrain neural progenitor cells (hNPC01) administered at escalated doses via single-dose intracerebral injection to subjects with stable chronic ischemic stroke., conditionsModule conditions: Chronic Ischemic Stroke, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 21, type: ESTIMATED, armsInterventionsModule interventions name: hNPC01, outcomesModule primaryOutcomes measure: Incidence of Treatment-Emergent Adverse Events as assessed by physiological parameters during 6 months after intracerebral injection of hNPC01, secondaryOutcomes measure: Incidence of Treatment-Emergent Adverse Events as assessed by physiological parameters during 12 months after intracerebral injection of hNPC01, otherOutcomes measure: Number of participants with motor function improvement as assessed by rating scales of Modified Rankin Scale (mRS) during 12 months of treatment, otherOutcomes measure: Number of participants with motor function improvement as assessed by rating scales of Fugl-Meyer Motor Scale (FMMS) during 12 months of treatment, otherOutcomes measure: Number of participants with motor function improvement as assessed by rating scales of NIH Stroke Scale (NIHSS) during 12 months of treatment, otherOutcomes measure: Number of participants with motor function improvement as assessed by rating scales of Barthel Index (BI) during 12 months of treatment, eligibilityModule sex: ALL, minimumAge: 30 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: XiangYa Hospital, status: RECRUITING, city: Changsha, state: Hunan, country: China, contacts name: Dan Li, role: CONTACT, phone: 15074875481, contacts name: Zhiquan Yang, MD, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 28.19874, lon: 112.97087, hasResults: False
protocolSection identificationModule nctId: NCT06299020, orgStudyIdInfo id: HLaRabta24, briefTitle: Risks of Intermittent Fasting in Patients With Primary Adrenal Insufficiency, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-04, primaryCompletionDateStruct date: 2024-04-20, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Hopital La Rabta, class: OTHER, descriptionModule briefSummary: In primary adrenal insufficiency, there is an increased risk of hypoglycaemia and dehydration. These risks have been little studied particularly during intermittent fasting. The present study aimed to assess these risks in a prospective study of 30 subjects with primary adrenal insufficiency. Patients will undergo a clinical examination, blood sampling and continuous glucose monitoring for fourteen days (one week of fasting and one week of non-fasting)., conditionsModule conditions: Primary Adrenal Insufficiency, conditions: Intermittent Fasting, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: intermittent fasting, outcomesModule primaryOutcomes measure: hypoglycemia, secondaryOutcomes measure: Dehydration, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06299007, orgStudyIdInfo id: HYH EC 052-66-01, secondaryIdInfos id: HYH EC 052-66-01, type: OTHER_GRANT, domain: Hatyai Hospital Education Center, briefTitle: Awareness of Iron Status Evaluation in UGIB, acronym: AISE, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-08-01, primaryCompletionDateStruct date: 2023-12-31, completionDateStruct date: 2023-12-31, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Hat Yai Medical Education Center, class: OTHER, descriptionModule briefSummary: BACKGROUND: Data on the awareness of the need to evaluate iron status and IDA prevalence in acute UGIB are limited.OBJECTIVES: This study aimed to investigate the rate of evaluation of iron status and prevalence of iron deficiency anemia (IDA) and the associated factors in patients with anemia hospitalized for acute upper gastrointestinal bleeding (UGIB)., conditionsModule conditions: Upper Gastrointestinal Bleeding, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 867, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: iron status measurement, secondaryOutcomes measure: Iron deficiency anemia, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hatyai Hospital, city: Hat Yai, state: Songkhla, zip: 90110, country: Thailand, geoPoint lat: 7.00836, lon: 100.47668, hasResults: False
protocolSection identificationModule nctId: NCT06298994, orgStudyIdInfo id: SBA 23/391, briefTitle: Determination of Body Awareness and the Functional Movement in Patients With COPD, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-08, primaryCompletionDateStruct date: 2025-03-08, completionDateStruct date: 2026-03-08, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Hacettepe University, class: OTHER, descriptionModule briefSummary: The aim of this study is to investigate body awareness and functional movement in patients with Chronic Obstructive Pulmonary Disease (COPD) compared to healthy controls., conditionsModule conditions: Pulmonary Disease, Chronic Obstructive, conditions: Postural; Defect, conditions: Movement, Abnormal, conditions: Pain, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Evaluation of functional movement, primaryOutcomes measure: Evaluation of Body Awareness, secondaryOutcomes measure: Functional exercise capacity, secondaryOutcomes measure: Respiratory muscle strength, secondaryOutcomes measure: Respiratory muscle endurance, secondaryOutcomes measure: Pain Severity, secondaryOutcomes measure: Pain threshold, secondaryOutcomes measure: Posture, secondaryOutcomes measure: Daily living activities, secondaryOutcomes measure: Severity of disease, secondaryOutcomes measure: Dyspnea, secondaryOutcomes measure: Symptoms, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Aynur Demirel, city: Ankara, zip: 06100, country: Turkey, geoPoint lat: 39.91987, lon: 32.85427, locations facility: Hacettepe University, city: Ankara, zip: 06100, country: Turkey, contacts name: Aynur Demirel, role: CONTACT, phone: +905545295057, phoneExt: 178, email: aynur.demirel@hacettepe.edu.tr, contacts name: hidaye yamikan, role: CONTACT, phone: +905349898724, email: hidaye.yamikan@hacettepe.edu.tr, contacts name: hidaye yamikan, role: SUB_INVESTIGATOR, contacts name: cansu akkus, role: SUB_INVESTIGATOR, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06298981, orgStudyIdInfo id: 2301, briefTitle: Pulse Rate and Breathing Rate Accuracy, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-12, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Nuralogix Corporation, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to conduct a Breathing Rate and Pulse Rate accuracy validation comparing the NuraLogix AMC-SDK to the Reference devices, an FDA cleared End Tidal Carbon Dioxide monitor (GE Datex-Ohmeda) and a standard ECG (GE Datex-Ohmeda) derived heart rate reference. This will be done by manually scoring the collected waveform for data analysis., conditionsModule conditions: Pulse Rate and Breathing Rate, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: noninvasive and investigational NuraLogix AMC-SDK, outcomesModule primaryOutcomes measure: Breathing rate accuracy validation, primaryOutcomes measure: Pulse rate accuracy validation, secondaryOutcomes measure: Pulse rate simulation, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 81 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Element Materials Technology, status: RECRUITING, city: Louisville, state: Colorado, zip: 80027, country: United States, contacts name: Monica Rabanal, role: CONTACT, geoPoint lat: 39.97776, lon: -105.13193, hasResults: False
protocolSection identificationModule nctId: NCT06298968, orgStudyIdInfo id: NFEC-2024-074, briefTitle: Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-25, primaryCompletionDateStruct date: 2025-02-25, completionDateStruct date: 2027-02-25, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Nanfang Hospital, Southern Medical University, class: OTHER, descriptionModule briefSummary: In this phase 2 study, the investigators aim to evaluate the efficacy and safety of combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab for patients with advanced and unresectable intrahepatic cholangiocarcinoma, conditionsModule conditions: Intrahepatic Cholangiocarcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 38, type: ESTIMATED, armsInterventionsModule interventions name: combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab, outcomesModule primaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: The disease control rate (DCR), secondaryOutcomes measure: Duration of response (DOR), secondaryOutcomes measure: The median progression free survival time (mPFS), secondaryOutcomes measure: The median overall survival time (mOS), secondaryOutcomes measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Nanfang Hospital of Southern Medical University, status: RECRUITING, city: Guangzhou, state: Guangdong, country: China, contacts name: Mengya Zang, role: CONTACT, phone: 86-20-62787430, email: zangmy@163.com, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06298955, orgStudyIdInfo id: OMS906-PNH-003, briefTitle: Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-19, primaryCompletionDateStruct date: 2026-12, completionDateStruct date: 2027-04, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Omeros Corporation, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to assess the long-term safety and tolerability of repeat-dose OMS906 5 mg/kg IV administration at 8-week intervals in patients with PNH., conditionsModule conditions: Paroxysmal Nocturnal Hemoglobinuria, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: OMS906 study drug, outcomesModule primaryOutcomes measure: To assess overall safety and tolerability of OMS906 administration at 8-week intervals in PNH patients., secondaryOutcomes measure: To assess efficacy measured by hemoglobin (Hgb)., secondaryOutcomes measure: To assess efficacy by transfusion requirements., secondaryOutcomes measure: To assess efficacy by measurement of lactate dehydrogenase (LDH)., secondaryOutcomes measure: To assess efficacy by measurement of reticulocyte count., secondaryOutcomes measure: To assess efficacy by measurement of clinical breakthrough hemolysis., secondaryOutcomes measure: To assess population PK Cmax of OMS906., secondaryOutcomes measure: To assess population PK AUC of OMS906., secondaryOutcomes measure: To assess population PK terminal half life of OMS906., secondaryOutcomes measure: To assess PD of OMS906, secondaryOutcomes measure: OMS906 anti-drug antibodies (ADA)., secondaryOutcomes measure: Assess the change in Functional Assessment of Chronic Illness Therapy (FACIT) fatigue score., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Omeros Investigational Site, status: NOT_YET_RECRUITING, city: Aachen, country: Germany, geoPoint lat: 50.77664, lon: 6.08342, locations facility: Omeros Investigational Site, status: NOT_YET_RECRUITING, city: Ulm, country: Germany, geoPoint lat: 48.39841, lon: 9.99155, locations facility: Omeros Investigational Site, status: RECRUITING, city: Lausanne, country: Switzerland, geoPoint lat: 46.516, lon: 6.63282, locations facility: Omeros Investigational Site, status: NOT_YET_RECRUITING, city: Kyiv, country: Ukraine, geoPoint lat: 50.45466, lon: 30.5238, locations facility: Omeros Investigational Site, status: NOT_YET_RECRUITING, city: Leeds, country: United Kingdom, geoPoint lat: 53.79648, lon: -1.54785, hasResults: False
protocolSection identificationModule nctId: NCT06298942, orgStudyIdInfo id: fac.med.24.9, briefTitle: Naturally Banded Versus Synthetic Banding of Sleeve Gastrectomy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2025-06-15, completionDateStruct date: 2025-07-15, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Minia University, class: OTHER, descriptionModule briefSummary: to compare banding sleeve gastrectomy using silicone ring Versus using natural flap ( round ligament of the liver), conditionsModule conditions: Obesity, Morbid, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 250, type: ESTIMATED, armsInterventionsModule interventions name: natural band, interventions name: silicone band, outcomesModule primaryOutcomes measure: total cost, primaryOutcomes measure: food intolerance, secondaryOutcomes measure: %EWL, secondaryOutcomes measure: complications rate, secondaryOutcomes measure: improvement of comorbidities, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06298929, orgStudyIdInfo id: 36264PR427/11/23, briefTitle: Medial Rectus Fenestration vs Recession for PAET, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-15, primaryCompletionDateStruct date: 2024-09-15, completionDateStruct date: 2024-10-15, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Mansoura University, class: OTHER, collaborators name: Tanta University, descriptionModule briefSummary: This prospective comparative study aims to compare medial rectus (MR) muscle fenestration and recession in patients with partially accommodative esotropia (PAET). The main question it aims to answer is whether MR fenestration is equally effective as MR recession for PAET.All patients will receive complete ophthalmic and orthoptic assessment. Patients will be randomly allocated using a random table to one of two groups; Group 1 will receive conventional MR recession, and Group 2 will receive MR fenestration., conditionsModule conditions: Partially Accommodative Esotropia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: medial rectus fenestration, interventions name: medial rectus recession, outcomesModule primaryOutcomes measure: Ocular alignment (measured in prism diopters), secondaryOutcomes measure: ocular motility, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tanta University, status: RECRUITING, city: Tanta, state: Gharbeya, country: Egypt, contacts name: Heba M Shafeik, MD, role: CONTACT, phone: +201227440829, email: heba.saeid@med.tanta.edu.eg, geoPoint lat: 30.78847, lon: 31.00192, hasResults: False